Topline results of the STRONG-HF trial point to significant clinical benefit from a strategy featuring early initiation and rapid uptitration of meds for patients hospitalized with heart failure.
Hyperkalemia is no reason for suboptimal guideline-directed heart failure medical therapy, given availability of at least one potassium-binding drug that seems to offer protection, researchers say.